


































































Therapeutic Advances in Neurological Disorders
journals.sagepub.com/home/tan 1
Ther Adv Neurol Disord
2021, Vol. 14: 1–10
DOI: 10.1 77/ 
17562864211030664
© The Author(s), 2021.  
Article reuse guidelines:  
sagepub.com/journals-
permissions
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
The term ‘radiologically isolated syndrome’ (RIS) 
was first coined in 2009 by Okuda et  al. and is 
applied to the incidental finding of lesions sugges-
tive of multiple sclerosis (MS) during brain mag-
netic resonance imaging (MRI).1 These lesions 
demonstrate dissemination in space and occur in 
subjects with a normal neurological examination 
and no history of typical MS symptoms. Since 
then, the risk of RIS evolving into MS has become 
probably the most studied RIS topic. Several 
independent observational cohort studies have 
shown that, within 5 years after detection of RIS, 
up to 30% of patients will experience a sympto-
matic demyelinating event and nearly two-thirds 
will progress radiologically with new lesions visi-
ble on magnetic resonance imaging (MRI).2–4 
Various predictors of increased risk of MS or clin-
ically isolated syndrome (CIS) conversion have 
been described, such as male sex,4 infratentorial 
and spinal lesions,2–4 a higher absolute number of 
lesions, pathological visual evoked potentials,3 a 
younger age at RIS diagnosis,3,4 CSF-specific oligo-
clonal bands (OCB),5 a pathological cerebrospinal 
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fluid (CSF) immunoglobulin G (IgG) index and 
recently also CSF neurofilament light chain con-
centration, measured by enzyme-linked immuno-
sorbent assay.3,5 Recently, the consortium 
studying the epidemiology of RIS worldwide 
(RISC) presented their 10-year follow-up results, 
identifying age, infratentorial and spinal cord 
lesions, positive oligoclonal bands in CSF at base-
line and the presence of gadolinium (Gd)-
enhancing lesions during follow up as significant 
predictors for the development of a first clinical 
event.6 However, despite the clinical need, there 
is so far no predictive score to estimate the risk of 
conversion of RIS to MS with a high enough 
specificity to avoid false negative results. The 
potential importance of early recognition of the 
subgroup of RIS patients at a high risk of develop-
ing MS is emphasized by existing data on CIS/
MS. This data from multiple placebo-controlled 
trials shows that the early introduction of disease 
modifying therapies (DMTs) prevents future dis-
ability.7–12 As RIS can also convert to MS, an 
analogous situation can be assumed and a reduced 
conversion rate in RIS patients treated with DMT 
is likely. Two large multi-centre, double-blinded, 
randomised clinical trials (TERIS) in Europe,13 
and (ARISE) in the United States (US),14 are 
ongoing to find out whether treatment of RIS 
reduces the risk of conversion to MS. The present 
study aimed to develop a clinical score to predict 
conversion of RIS to MS in a large monocentric 
cohort of patients with RIS.
Methods
A total of 31 patients with RIS were identified ret-
rospectively by screening medical records of all 
patients seen at the neurological department of 
the University Hospital of Bern (Switzerland), a 
tertiary care centre, for the diagnoses ‘radiologi-
cally isolated syndrome’ and ‘RIS’ between 2004 
and 2017. Diagnosis of RIS adhered to Okuda’s 
criteria (2009).1 The following data, recorded 
during routine clinical examinations, were 
extracted for our study: five sociodemographic 
variables (female sex, age, abnormal neurological 
status at RIS-diagnosis, family history of MS, and 
of other autoimmune disease), four serological 
markers [anti-nuclear antibody (ANA) in serum, 
perinuclear anti-neutrophil cytoplasm antibodies 
(p-ANCA), cytoplasmic anti-neutrophil cyto-
plasm antibodies (c-ANCA) and cardiolipin IgG], 
five CSF parameters (CSF albumin, CSF protein, 
CSF immune cells, CSF-specific oligoclonal 
bands and IgG in CSF) and seven MRI parame-
ters (Gd-enhancing lesions, cerebellar hemisphere 
lesions, periventricular lesions, brainstem lesions, 
juxtacortical lesions, deep white matter lesions 
and white matter lesion load). In an exploratory 
approach, we pre-selected the above-mentioned 
23 sociodemographic, serological, CSF- and 
MRI-characteristics to be investigated as possible 
predictors of conversion to MS from all patient 
information given in the digital hospital informa-
tion system. These variables were chosen because 
either they were investigated in previous studies 
or, in the opinion of the authors, could be biologi-
cally plausible factors of autoimmunity.
For coding of variables, we referred to the code-
book (Supplemental material 1). CSF and serum 
parameters were analysed in the main laboratory 
of the University Hospital Bern, Switzerland. 
MRIs were acquired at the University Hospital 
Bern using 3 and 1.5 Tesla MRI scanners 
(Siemens Healthcare, Erlangen, Germany) fol-
lowing our in-house standard operating proce-
dures (see Supplemental material 2). The 
involvement of the following regions of the cen-
tral nervous system in the MRI was assessed qual-
itatively: corpus callosum, brainstem and 
cerebellar hemisphere, juxtacortical and periven-
tricular. Gd-enhancing lesions were identified on 
post-contrast T1-weighted scans. MS diagnosis 
followed the 2010 revised McDonald criteria.12 
Patients were followed up until conversion to MS 
or, in non-converters, for a maximum period of 
3 years. The time to conversion to MS was 
assessed by calculating the interval between the 
date of the MRI from which RIS was diagnosed 
and the date of conversion.
Statistical analysis
Ordinal or continuous variables are presented as 
median and 25th–75th percentiles, whereas 
dichotomous variables are presented as frequen-
cies. An exception to this rule was made for sensi-
tivity, specificity and area under the curve (AUC), 
which are presented as mean and standard devia-
tion (SD). Sensitivity and specificity were calcu-
lated using the ‘VassarStats research calculator’ 
(Poughkeepsie, NY, USA). All other analyses 
were performed with SPSS 25 (IBM, Armonk, 
NY, USA).
The significant predictors of conversion to MS in 
RIS patients were identified statistically using 
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Kaplan–Meier log rank statistic for comparison of 
two groups. Therefore, classification of variables 
was necessary prior to analysis. Here, continuous 
variables with biological plausible cut off values 
for pathological values were classified using the 
upper limit of the respective reference range, e.g., 
CSF protein concentration >0.4 g/l. Continuous 
variables without such a given cutoff, like age, 
were analysed using receiver operating character-
istic curves to identify the value which differenti-
ates best between converters and non-converters. 
Finally, all significant predictors of conversion to 
MS were integrated into a score called ‘the RIS–
MS prediction score’.
For this purpose, the significant predictors were 
added up by their chi-squared value. This sum 
was divided by the number of available tests in 
order to adjust for missing variables in some 
patients. Again, an ROC analysis was performed 
to identify the optimal cut-off to differentiate 
between RIS patients who convert to MS and 
those who do not. Specificity and sensitivity were 
then calculated together with 95% confidence 
intervals (CIs). The aim of this mathematical pro-
cedure was to be able to predict a high likelihood 
of RIS conversion to MS to develop a tool that 
would justify early initiation of immunotherapy. 
Therefore, specificity was rated more important 
than sensitivity to keep the rate of false positives 
low.
Ethical approval
This study was approved by the responsible can-
tonal ethics committee (registration no. KEK-BE 
2017-01369). Because of the retrospective nature 
of the analysis with pseudonymised patient data, 
separate informed consent was waived by the 
committee. This corresponds to the local legisla-
tion. For patients seen after the introduction of 
the general consent (February 2015), the pres-
ence of the patients’ consent was checked before 
inclusion in the analysis.
Results
Patient population and conversion to MS
Retrospective analysis of medical records identi-
fied 31 patients fulfilling the 2009 Okuda criteria 
who were diagnosed in University Hospital Bern, 
Switzerland between 2004 and 2017 (Table 1). 
Within the follow-up period of up to 3 years, 5 of 
these RIS patients (16.1%) converted to MS. The 
times of conversion were distributed as follows: 
first year: 4/31; second year: 0/27; third year 1/27.
Role of sociodemographic characteristics and 
disability in RIS patients converting to MS
To identify sociodemographic factors associated 
with conversion to MS in our RIS cohort, 
Kaplan–Meier curves were plotted and log rank 
tests performed for sex (female 21/31), age 
(<40 years 16/31), abnormal neurological find-
ings at RIS diagnosis (3/31), family history of MS 
(4/31) and family history of any other autoim-
mune disease including MS (7/31). Within this 
set of variables, only female sex demonstrated a 
trend towards earlier and more frequent conver-
sion to MS (Table 2). Three of our patients for-
mally had an abnormal neurological exam at 
diagnosis of RIS. However, none of the abnormal 
findings were related to this diagnosis and they 
were not suggestive of MS (for details, see 
Supplemental material 3). Fittingly, abnormal 
neurological findings at RIS diagnosis did not 
reach statistical significance in further analysis 
(Table 2).
Role of serological immune parameters in RIS 
patients converting to MS
Analyses were performed for p-ANCA in 27 
patients, c-ANCA in 31, cardiolipin IgG in 16 
and ANA in 26 of the 31 RIS patients. Two of the 
ANA-positive subjects presented autoimmune 
comorbidities [psoriasis (n = 1), relapsing uveitis 
(n = 1)]. Except ANA positivity (10/26), no other 
immunological parameter was detectable in any 
of the RIS patients (Table 1). Moreover, ANA 
positivity also predicted RIS conversion to MS 
(Table 2).
Role of CSF parameters in RIS patients 
converting to MS
CSF data was available for 27 of the 31 RIS 
patients. Analysis of albumin concentration 
(26/27), protein concentration (27/27), IgG con-
centration (26/27), OCBs (25/27) and number of 
immune cells in the CSF (27/27) showed that 
only CSF immune cell count and CSF albumin 
concentration demonstrated significant potential 
for predicting conversion to MS (Table 1).
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Role of MRI parameters in RIS patients 
converting to MS
MRI of the cerebrum with T1 post-contrast 
sequences was obtained for all (31/31) patients. 
The presence of Gd enhancement, lesions in the 
corpus callosum, cerebellar hemisphere, brain-
stem, periventricular lesions, deep white matter 
and juxtacortical lesions, as well as the absolute 
number of lesions dichotomised according to 
whether there were ⩽10 or >10 was assessed. Of 
these parameters, Gd enhancement, cerebellar 
hemisphere lesions and brainstem lesions were 
associated with a risk of conversion to MS in sur-
vival analysis (Table 1).
RIS–MS prediction score
All six significant predictors of conversion to MS 
were included in the RIS–MS prediction score 
(Table 2). Running a ROC analysis demonstrated 
Table 1. Baseline characteristics.
Baseline characteristics Median IQR n Missing
Age at RIS diagnosis (years) 41.0 24.0 31/31 0
CSF cell count per µl 1.0 3.0 27/31 0
CSF protein (g/l) 0.33 0.16 27/31 0
CSF albumin (mg/l) 210 101.5 26/31 0
CSF IgG (mg/l) 26.0 22.0 26/31 0
Time to MS conversion (years) 0.67 2.41 5/31 0
Follow up in non-convertersa (years) 0.58 1.42 22/26 4
 % N  
Female 67.7 21/31 0
Abnormal neurological status at RISb 9.7 3/31 0
Frequency of CSF analysis 87.10 27/31 0
CSF-specific OCB (+) 36.0 9/25 6
ANA positivity (serum) 32.3 10/26 5
c-ANCA positivity (serum) 0.0 0/31 0
p-ANCA positivity (serum) 0.0 0/27 4
Cardiolipin IgG positivity (serum) 0.0 0/16 15
Number of cMRIs performed 100 31/31 0
MRI lesion location
 Lesions in corpus callosum 67.7 21/31 0
 Infratentorial 45.2 14/31 0
 Gd enhancement 29.0 9/31 0
aMS conversion was defined using clinical and MRI parameters and applied the 2010 McDonald criteria (see Methods).
bUnrelated to RIS and not suggestive of MS, see Supplemental material 3.
ANA, anti-nuclear antibodies; c-/p-ANCA, cytoplasmic/perinuclear anti-neutrophil cytoplasm antibodies; cMRI, magnetic 
resonance imaging of the cerebrum; CSF, cerebrospinal fluid; Gd, gadolinium; IQR, interquartile range; n, number of 
observations; OCB, oligoclonal bands.
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that a cut-off of >4.37 points had the highest spec-
ificity (1.0, 95% CI 0.84–1.00) and an acceptable 
sensitivity (0.6, 95% CI 0.17–0.93) for prediction 
of RIS conversion to MS (Figure 1). Furthermore, 
the survival analysis yielded a significant difference 
of RIS patients converting to MS over a maximum 
follow up of 3 years between those above and those 
below the cut-off value of 4.37 (Figure 2).
Table 2. Log-rank test statistic.
Variable χ2 p value N
Sociodemographic variables
 Female sex 3.04 0.08 31
 Age (⩽40 versus >40 years) 1.91 0.17 31
 Abnormal neurological status at RIS (no versus yes) 1.26 0.26 31
Family history of:
  MS 0.05 0.82 31
  Any other AID 1.26 0.26 31
Serological immune parameters
 ANA positivity (serum) 4.66 0.03 26
CSF parameters
 Elevated albumin (>300 mg/l) 5.15 0.02 26
 Elevated protein (>0.4 g/l) 0.33 0.56 27
 Elevated immune cells (>5 M/l) 8.42 0.004 27
 CSF-specific OCB (positive) 3.32 0.07 25
 Elevated IgG (⩾40 mg/l) 0.47 0.49 26
MRI parameters
 Callosal lesion (yes) 0.005 0.943 31
 Gadolinium enhancement (yes) 8.158 0.004 31
 Lesion load WM (⩽10 versus >10) 1.07 0.301 31
 Cerebellar hemisphere lesions 14.727 <0.001 31
 Periventricular lesions 0.09 0.761 31
 Brainstem lesions 9.847 0.002 31
 Juxtacortical lesions 1.787 0.181 31
 Deep WM lesions 0.426 0.514 31
RIS–MS prediction score 28.82 <0.001 31
AID, autoimmune disease; ANA, anti-nuclear antibody; CSF, cerebrospinal fluid; Ig, immunoglobulin; MRI, magnetic 
resonance imaging; MS, multiple sclerosis; OCB, oligoclonal bands; RIS, radiologically isolated syndrome; WM, white matter. 
Values in bold indicate variables predicting conversion to ms.
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Discussion
Identifying accurate predictors of the risk of RIS 
patients experiencing a clinical event and pro-
gressing to MS is a considerable challenge. The 
ability to define these risk predictors could be par-
ticularly useful because treatment with disease-
modifying agents may be more beneficial for RIS 
patients before conversion to MS. To answer the 
question, if RIS patients should be treated with 
DMT two large multi-centre, double-blind, ran-
domised clinical trials (TERIS) in Europe and 
(ARISE) in the US are ongoing.13,14 However, a 
potential therapy of RIS patients is only feasible if 
these predictors can be defined accurately given 
that RIS patients are an especially vulnerable 
population as they are free of MS symptoms. 
Thus, false positive predictions should be avoided 
to prevent unnecessary medical testing, treatment 
and psychological stress.
Against this background, we tried to develop and 
statistically design a prediction score focussing on 
Figure 1. ROC analysis to predict conversion to MS in 
RIS patients using the RIS–MS prediction score.
AUC, area under the curve; CI, confidence interval; MS, 
multiple sclerosis; RIS, radiologically isolated syndrome; 
ROC, receiver operating characteristic.
Figure 2. Kaplan–Meier curve after stratification by RIS–MS prediction score (cut-off ⩾4.37 points): 
conversion to MS within 3 years; statistic, log rank test: p value = 0.004.
MS, multiple sclerosis; RIS, radiologically isolated syndrome.
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high specificity. Univariate analysis identified six 
significant predictors of conversion of RIS to MS 
that were included in the RIS–MS prediction 
score (variables: Gd enhancement, brainstem and 
cerebellar hemisphere lesions, CSF immune cell 
count, CSF albumin concentration and ANA pos-
itivity of serum). With a cut-off of ⩾4.37 points, 
this score can predict the conversion of RIS to MS 
with a specificity of 1.0 (95% CI 0.84–1.00) and a 
sensitivity of 0.6 (95% CI 0.17–0.93).
Looking at the six predictors in more detail, 
infratentorial involvement seen on baseline imag-
ing, and known to be important in CIS,15 was 
predictive of RIS conversion to MS in our cohort 
too, as we found brainstem and cerebellar hemi-
sphere lesions to be significant risk predictors. 
Infratentorial lesions have long been considered 
typical of MS and this topography was incorpo-
rated into the Fazekas and the Barkhof criteria 
and, more recently, the MAGNIMS consensus 
criteria. Lebrun et  al.2 and Okuda et  al.3 recog-
nized infratentorial lesions as a possible prognos-
tic factor for clinical progression in RIS patients. 
Furthermore, a recent publication of the 10-year 
follow up of the consortium studying the epide-
miology of RIS worldwide (RISC) identified 
infratentorial lesions as a predictor for the devel-
opment of a first clinical event.6 Thus, our find-
ings fit well with the literature.
Gd enhancement in brain lesions reflects distur-
bances of the blood–brain barrier (BBB) with high 
sensitivity. Disruption of the BBB is an early event 
in the development of inflammatory lesions in MS 
and a robust predictor of the occurrence of 
relapses.16 Lebrun et  al.2 demonstrated that RIS 
patients with Gd-enhancing lesions in baseline 
imaging had a substantially increased risk of devel-
oping new lesions, which we also found in our 
study. In another study the presence of gadolin-
ium-enhancing lesions during follow up was also 
associated with the risk of first clinical event.6 
Furthermore, in accordance with the 2017 
McDonald criteria, the finding of enhancing 
lesions in combination with non-enhancing lesions 
meets the criterion of dissemination in time, even 
in the first MRI scan, independently of clinical 
symptoms.17
The prognostic role of CSF parameters in predict-
ing conversion of RIS to MS was studied in 451 
RIS patients. The authors identified a pathologi-
cal CSF IgG index or the presence of CSF-specific 
OCB as risk factors.4 Our finding that elevated 
CSF immune cell count and elevated CSF albu-
min concentration may predict conversion of RIS 
to MS emphasizes the importance of CSF analy-
sis. Our findings are in line with those of Lotan 
et al., who studied a cohort of MS patients with 
CSF pleocytosis.18 These patients had a higher 
annualised relapse rate and a steeper slope of the 
Expanded Disability Status Scale score through-
out the follow-up period. We suggest that this 
finding in MS patients can also be applied to RIS 
patients, as our data showed a higher likelihood of 
conversion to MS in RIS patients with CSF pleo-
cytosis. The elevated CSF albumin levels reflect 
disturbances of the BBB and is in line with our 
above-mentioned finding that Gd enhancement in 
MRI may also play a predictive role. In our study, 
CSF OCB showed a trend at a 90% level of sig-
nificance towards early conversion. Interestingly, 
another study also found no statistically signifi-
cant predictive value of CSF OCB.2
In our study, elevated CSF albumin predicted 
RIS conversion to MS, as did a pathological albu-
min quotient. However, the pathological albumin 
quotient showed a weaker correlation to RIS con-
version compared with elevated CSF albumin 
(p = 0.031 versus p = 0.02) and a lower specificity 
(0.86, 95% CI 0.63–0.96 versus 0.95, 95% CI 
0.74–0.9975). As both variables have a strong 
correlation (Pearson correlation coefficient 0.99 
p < 0.001), it is not possible to include both of 
them in our score. Therefore, we chose to include 
elevated CSF albumin in our score and to omit a 
pathological albumin quotient as another poten-
tial variable, as in this study we rated specificity 
more important than sensitivity to keep the rate of 
false positives low.
Finally, the presence of ANA in our RIS cohort is 
noteworthy. Collard et  al. observed that ANA-
positivity was more frequent in MS patients than 
in healthy controls and suggested an association 
with MS disease activity.19 These investigators 
hypothesized that ANA is a product of systemic 
immune dysregulation, which is known to occur 
not only in systemic autoimmune diseases but also 
in MS. Further, they postulated that the presence 
of ANA might be a marker of disease activity or of 
response to therapy, which is also supported by 
the work of Spadaro et  al.20 ANA also occurred 
commonly in patients with RIS.21 However, ANA 
are generally thought to be a nonspecific and 
unimportant marker of autoimmunity in people 
Therapeutic Advances in Neurological Disorders 14
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with MS. In our analysis, we found ANA positiv-
ity as a risk factor for conversion of RIS to MS. In 
26 patients with ANA measurements, 10 patients 
had positive ANA values. Of those 10 patients, 4 
patients eventually converted from RIS to MS, 
whereas 6 did not. Therefore, ANA positivity was 
2.8 times more frequent in converters than in non-
converters in our cohort. Due to the small number 
of patients, the ANA titre did not reach a statisti-
cal significance as a risk factor for conversion of 
RIS to MS in our cohort. If we go back and look 
at the literature, Collard et  al. found ANA in a 
frequency of 22.5% in their MS cohort and in 16 
patients tested twice, ANA occurrence also corre-
lated with MS disease activity.19 They denomi-
nated the ANA in terms of disease specificity as 
‘false positive’ as they are not associated directly 
with MS. However, ANA might reflect the ‘non-
sense’ antibody production 19. We hypothesize 
that presence of ANA might be indicative for the 
state of activation of the dysregulated immune sys-
tem in people with MS. However, as mentioned 
before, more than the association between positive 
and negative ANA and RIS conversion cannot be 
shown by our data due to overall small number of 
cases. In our opinion, in addition to obvious mark-
ers of disease activity, matching of multicentric 
study cohorts to increase sample size and inclu-
sion of broader non-CNS specific markers of 
autoimmunity could be highly valuable in studies 
about RIS. We therefore hope that our article, 
with all the limitations of a retrospective study and 
small sample size, stimulates researchers to join 
forces to investigate immunological markers, like 
ANA, on their predictive value for conversion to 
MS in people with RIS. The ongoing prospective 
clinical trials, to which our centre also contributes 
in terms of the TERIS study, would give an ideal 
opportunity to conduct broader immunological 
studies in people with RIS. Thus, further research 
in this field is needed.
Our study has several significant limitations. 
First, it was a retrospective, non-standardized 
study resulting in different intervals and examina-
tions/paraclinical tests for clinical RIS surveil-
lance in routine care.
Another significant limitation is the absence of 
spinal MRI in the analysis, which was shown to be 
an important predictor of conversion to MS in 
other studies, including the largest RIS series by 
Okuda et al. with 451 patients.4 Due to the retro-
spective, non-standardized nature of our study, 
this data was missing in the majority of our patients 
(29/31), as a spinal MRI was not performed rou-
tinely in our centre at that point in time.
Thirdly, four patients who did not convert to MS 
during the study period were lost to follow up. 
Furthermore, our maximal follow-up period was 
only 3 years, so we cannot rule out the possibility 
that patients with RIS converted to MS later on. 
The short follow-up period is because a signifi-
cant number (12 of 31) of the included subjects 
was diagnosed with RIS in 2017 or at the end of 
2016; therefore, at the time this manuscript was 
written (2020) follow up was only available for up 
to 3 years for these patients.
As we studied a monocentric cohort with a small 
number of subjects, our statistical results need 
verification in a larger, multicentric cohort espe-
cially as, in total, only 5 of 31 patients converted 
from RIS to MS. Thus, caution in the interpreta-
tion of our data is required, which is reflected in 
the fact, that key risk factors previously identified 
in larger RIS studies did not reach statistical sig-
nificance or where not included in our study due 
to lack of data (such as spinal cord lesions). 
Moreover, the results are based on a univariate 
analysis which is statistically weaker, compared 
with multivariate analysis. However, as for exam-
ple spinal lesions (representing one of the major 
risk factors) were not included into the statistical 
procedure, our data could potentially be com-
pared with univariate analyses of other RIS cohort 
studies. Therefore, standardized studies with a 
larger number of patients are needed to verify our 
findings and help improve estimates of risk as 
standardized diagnosis and treatment of RIS 
patients is crucial.
Lastly, two of the variables identified as signifi-
cant risk factors for conversion to MS (ANA posi-
tivity and high CSF albumin) lack specificity for 
CNS demyelination from a biological point of 
view. Concerning elevated CSF albumin, a pos-
sible explanation for our results is that this value 
reflects disturbances of the BBB, which is in line 
with our finding that Gd enhancement in MRI 
may also play a predictive role. Nonetheless, to 
the best of our knowledge, no other study has 
investigated these variables as possible predictors 
of conversion to MS.
In conclusion, in our monocentric cohort, our RIS–
MS prediction score, which consists of readily 
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available MRI variables (Gd enhancement, brain-
stem and cerebellar hemisphere lesions), CSF vari-
ables (CSF immune cell count and CSF albumin 
concentration) and serum variables (ANA) allowed 
prediction of conversion of RIS to MS with high 
specificity and acceptable sensitivity. The present 
study has an exploratory character and several limi-
tations inherent to the retrospective nature, small 
sample size and investigated number of variables 
with the possibility that our observations might be 
coincidental. Thus, our work should not be 
regarded as a stand-alone diagnostic tool for pre-
diction of MS-risk in RIS, but rather serve as an 
input for further research in the field of RIS to pre-
dict conversion to MS by using multiple domain 
prediction scores. Therefore, the score presented 
here should first be verified by independent cohorts, 
and in the future a validated prediction score could 
help to identify the patients who need a more care-
ful monitoring for conversion to MS and therefore, 
help in deciding which patients might benefit from 
initiation of early treatment, as no approved thera-
peutic options are currently available.
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